Han Jae Ho, Suh Chang-Hee, Jung Ju-Yang, Nam Jin-Young, Kwon Jee Eun, Yim Hyunee, Kim Hyoun-Ah
Department of Pathology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon, 443-380, South Korea.
Department of Rheumatology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon, 443-380, South Korea.
Arthritis Res Ther. 2015 Sep 19;17(1):260. doi: 10.1186/s13075-015-0773-4.
C-X-C motif chemokine 10 (CXCL10) is produced in response to interferon-γ, and tumor necrosis factor-α (TNF-α) triggers the accumulation of activated lymphocytes. CXCL13 is constitutively expressed in secondary lymphoid tissues, and the expression is upregulated by TNF-α, via T cell stimulation. It appears that CXCL10 and CXCL13 could play a potential role in the pathogenesis of adult-onset Still's disease (AOSD), therefore, we investigated the associations between CXCL10 and CXCL13 levels and clinical manifestations in patients with active AOSD.
Blood samples were collected from 39 active AOSD patients, 32 rheumatoid arthritis (RA) patients and 40 healthy controls (HC). Of the AOSD patients, follow-up samples were collected from 15 9.6 ± 9.2 months later. Serum levels of CXCL10 and CXCL13 were determined using enzyme-linked immunosorbent assay. CXCL10, CXCL13, and C-X-C chemokine receptor type 3 (CXCR3) expression levels in biopsy specimens obtained from 26 AOSD patients with skin rashes were investigated via immunohistochemistry.
The CXCL10 levels in AOSD patients (1,031.3 ± 2,019.6 pg/mL) were higher than in RA (146.3 ± 91.4 pg/mL, p = 0.008) and HC (104.4 ± 47.9 pg/mL, p = 0.006). Also, the CXCL13 levels of AOSD patients (158.8 ± 151.2 pg/mL) were higher than those of RA (54.4 ± 61.1 pg/mL, p < 0.001) and HC (23.5 ± 18.1 pg/mL, p < 0.001). Serum CXCL10 levels correlated with ferritin and systemic scores. Serum CXCL13 levels correlated with those of hemoglobin, C-reactive protein, ferritin, and albumin, and systemic scores. In follow-up AOSD patients, the levels of CXCL10 and CXCL13 fell significantly (153.7 ± 130.1 pg/mL, p = 0.002, and 89.1 ± 117.4 pg/mL, p = 0.001, respectively). On immunohistochemistry, the percentages of inflammatory cells expressing CXCL10 ranged from 1 to 85%, CXCL13 from 1 to 72%, and CXCR3 from 2 to 65%. The percentage of CXCL10-positive inflammatory cells was higher in skin biopsy samples exhibiting mucin deposition than in those that did not (p = 0.01). CXCL13 levels were correlated with those of CD4 and CD68.
Serum CXCL10 and CXCL13 levels may serve as clinical markers for assessment of disease activity in AOSD. CXCL10/CXCR3 and CXCL13 may contribute to the inflammatory response, especially skin manifestations thereof, in AOSD.
C-X-C基序趋化因子10(CXCL10)是在γ干扰素的作用下产生的,而肿瘤坏死因子-α(TNF-α)会引发活化淋巴细胞的聚集。CXCL13在次级淋巴组织中持续表达,且其表达通过T细胞刺激被TNF-α上调。CXCL10和CXCL13似乎可能在成人斯蒂尔病(AOSD)的发病机制中发挥潜在作用,因此,我们研究了CXCL10和CXCL13水平与活动性AOSD患者临床表现之间的关联。
采集了39例活动性AOSD患者、32例类风湿关节炎(RA)患者和40例健康对照(HC)的血样。在AOSD患者中,于9.6±9.2个月后采集了随访样本。采用酶联免疫吸附测定法测定血清CXCL10和CXCL13水平。通过免疫组织化学研究了26例有皮疹的AOSD患者活检标本中CXCL10、CXCL13和C-X-C趋化因子受体3(CXCR3)的表达水平。
AOSD患者的CXCL10水平(1,031.3±2,019.6 pg/mL)高于RA患者(146.3±91.4 pg/mL,p = 0.008)和HC(104.4±47.9 pg/mL,p = 0.006)。此外,AOSD患者的CXCL13水平(158.8±151.2 pg/mL)高于RA患者(54.4±61.1 pg/mL,p < 0.001)和HC(23.5±18.1 pg/mL,p < 0.001)。血清CXCL10水平与铁蛋白及全身评分相关。血清CXCL13水平与血红蛋白、C反应蛋白、铁蛋白、白蛋白水平及全身评分相关。在随访的AOSD患者中,CXCL10和CXCL13水平显著下降(分别为153.7±130.1 pg/mL,p = 0.002,和89.1±117.4 pg/mL,p = 0.001)。免疫组织化学显示,表达CXCL10的炎症细胞百分比为1%至85%,CXCL13为1%至72%,CXCR3为2%至65%。在有黏蛋白沉积的皮肤活检样本中,CXCL10阳性炎症细胞的百分比高于无黏蛋白沉积的样本(p = 0.01)。CXCL13水平与CD4和CD68水平相关。
血清CXCL10和CXCL13水平可作为评估AOSD疾病活动度的临床标志物。CXCL10/CXCR3和CXCL13可能参与AOSD的炎症反应,尤其是其皮肤表现。